Meeder Asset Management’s ACELYRIN SLRN Stock Holding History

Meeder Asset Management’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-122	Closed	-$1.24K	–	562
2023 Q3	$1.24K	Buy	+122	New	+$2.59K	﹤0.01%	465

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meeder Asset Management's SLRN Position: Q4 2023 in Review

Meeder Asset Management sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 122 shares — an estimated $1.24K sold.

Meeder Asset Management first reported a position in SLRN in Q3 2023 and held it in 1 quarter. The position peaked at $1.24K in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Meeder Asset Management reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Meeder Asset Management sold 122 ACELYRIN shares in Q4 2023, an estimated $1.24K.
Meeder Asset Management first reported a position in ACELYRIN in Q3 2023 and held it in 1 quarter.
Meeder Asset Management's ACELYRIN position peaked at $1.24K in Q3 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Meeder Asset Management's 13F filing for Q4 2023, filed 25 Jan 2024.